FAQ: Quantum BioPharma Ltd. Corporate Update on Debt Settlement, RSU Grants, and Advisor Changes
Summary
Quantum BioPharma Ltd. announced corporate actions including settling debt through share issuance, granting RSUs to clinical advisors tied to regulatory milestones for its Lucid MS program, and the termination of an advisor's agreement. These actions are part of the company's strategy to advance its neurodegenerative and metabolic disorder treatments while managing financial obligations.
What corporate actions did Quantum BioPharma Ltd. announce?
Quantum BioPharma announced the settlement of $26,812.50 in outstanding debt through the issuance of 1,102 Class B shares, granted 800 restricted share units (RSUs) each to clinical advisors Peter Stys and Jack Antel, and confirmed that Kevin Malone is no longer serving as an advisor to the board.
When did these corporate actions take effect?
The debt settlement was approved by the board on August 12, 2025, the RSU grants were made on August 15, 2025, and Kevin Malone’s termination as an advisor was effective August 15, 2025.
How was the outstanding debt settled?
The debt of $26,812.50 was settled through the issuance of 1,102 Class B shares at a deemed price of $24.33 per share.
What are the terms of the RSU grants to the clinical advisors?
The RSUs granted to Peter Stys and Jack Antel vest based on regulatory milestones for the company’s Lucid MS program and are subject to a four-month-plus-one-day statutory hold under CSE policy, with no registration under the U.S. Securities Act.
Why is the Lucid MS program significant to Quantum BioPharma?
Lucid-MS is Quantum BioPharma’s lead compound, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models, targeting the underlying mechanism of multiple sclerosis, which is a key focus of the company’s neurodegenerative disorder treatments.
What is Quantum BioPharma’s involvement with Celly Nutrition and UNBUZZD™?
Quantum BioPharma retains 25.71% ownership of Celly Nutrition as of June 30, 2024, receives royalty payments of 7% of sales from UNBUZZD™ up to $250 million (then 3% in perpetuity), and keeps 100% rights to develop similar products for pharmaceutical uses.
Where can investors find more information about Quantum BioPharma?
The latest news and updates are available in the company’s newsroom at https://ibn.fm/QNTM, and the full press release can be viewed at https://ibn.fm/RpGC0.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 171712